Fufangdanshen Tablets + Placebo

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vascular Dementia

Conditions

Vascular Dementia

Trial Timeline

Sep 1, 2012 → Dec 1, 2015

About Fufangdanshen Tablets + Placebo

Fufangdanshen Tablets + Placebo is a phase 2 stage product being developed by Guangzhou Baiyunshan Pharmaceutical Holdings for Vascular Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT01761227. Target conditions include Vascular Dementia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01761227Phase 2Completed

Competing Products

20 competing products in Vascular Dementia

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
EvacetrapibEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
52
Rosuvamibe + MonorovaYuhanApproved
85
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
85
Rosuvamibe + MonorovaYuhanApproved
85
olmesartanDaiichi SankyoPre-clinical
23
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
85
Avacincaptad PegolAstellas PharmaPhase 1
33
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
52
LexiscanAstellas PharmaPhase 2
52
YM872 (zonampanel)Astellas PharmaPhase 2
52
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
52